Usher Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Usher Syndrome Market Outlook
Thelansis’s “Usher Syndrome Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Usher Syndrome treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Usher
Syndrome Overview
Usher
syndrome is a group of inherited disorders characterized by dual sensory
impairment of the auditory and visual systems. It is the most common cause of
combined sight and hearing loss, accounting for more than half of
deaf-blindness cases. Nine causative genes have been identified and confirmed
responsible for the syndrome when mutated, including MYO7A, USH1C, CDH23,
PCDH15, and USH1G for Usher type 1; USH2A, ADGRV1, and WHRN for Usher type 2;
and CLRN1 for Usher type 3. Usher syndrome is clinically and genetically
heterogeneous and is divided into three distinct clinical subtypes: Usher 1,
Usher 2, and Usher 3. Usher 1 is the most severe subtype, in which patients
exhibit severe to profound bilateral congenital sensorineural hearing loss,
most frequently non-progressive, with vestibular areflexia. It accounts for
approximately 25-44% of all Usher syndrome cases. Usher 2 represents over half
of all cases. Sensorineural hearing loss is typically described as sloping,
mild to moderate in the low frequencies and severe to profound in the high
frequencies.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment